Browse drugs

…59/81 (72.8%) (AO)/43/327 (13.1%) and 55/327 (16.8%) (NRI) with adalimumab. Initial non-responders/incomplete responders benefited from sw…

… full analysis set, 113 received GUS 100mg SC Q8W, 115 received GUS 200mg SC Q4W, and 58 received PBO. 91.3% completed the 24 weeks…

…ET-CT. The remaining patients received oral prednisolone and/or methotrexate therapy. Of the 20 CS patients, 8 (40%) had left ventricular (L…

…isomerase I positive. TCZ monotherapy was used in 29% of cases, methotrexate was the most frequent combined treatment (35%). In SSc-associat…

…analyze long term outcome of patients with SSc-ILD treated with tocilizumab (TCZ), rituximab (RTX), and abatacept (ABA) which became availa…

…with intravenous cyclophosphamide (cumulative 6 g), followed by mycophenolate mofetil (2 g/day), leading to initial clinical and laboratory improveme…

…development of a new digital ulcer despite at least 24 weeks of bosentan therapy. We included patients who were receiving concurrent tre…

… kinase (JAK) – STAT signalling in PSM pathogenesis, suggesting ruxolitinib, a JAK 1/2 inhibitor, as potential therapeutic option [N Engl J…

… MTX therapy was documented in 2 patients, who were switched to mophetil micofenolate. A concordance between mLOSSI, IRT and US was found in 5 cases …

…ial lung disease (68%). The top first-line drugs of choice were mycophenolate mofetil (47%), methotrexate (28%) and hydroxychloroquine (20%).Conclusi…

….4% of patients) whereas systemic agents, such as methotrexate, hydroxychloroquine, steroids and cyclosporine (in 38.6% of patients), were reserve…

…cases. Systemic treatments included corticosteroids (39.1%) and methotrexate (27.6%), with adjunctive phototherapy used in 24.5% of patients…